Search Result

Results for "

antiallodynic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Adenylate Cyclase (1) Apoptosis (1) Cannabinoid Receptor (1) Dopamine Receptor (6) Endogenous Metabolite (8) GCGR (1) Opioid Receptor (2) Proteasome (1) Sigma Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (3) Inflammation/Immunology (2) Neurological Disease (13)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15451

MDA 19 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-112692

AT-121	Opioid Receptor	Neurological Disease
AT-121 is a bifunctional nociception and mu opioid receptor agonist, with K_is of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .

HY-145830

AC1-IN-1	Adenylate Cyclase	Neurological Disease
AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC₅₀ of 0.54 µM. AC1-IN-1 displays modest antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity .

HY-N0630

Shanzhiside methyl ester	GCGR	Neurological Disease
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-112692A

AT-121 hydrochloride	Opioid Receptor	Neurological Disease
AT-121 hydrochloride is a bifunctional nociception and mu opioid receptor agonist, with K_is of 3.67 and 16.49 nM, respectively. AT-121 hydrochloride is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .

HY-N0304

L-DOPA Maximum Cited Publications 13 Publications Verification Levodopa; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-149853

AD186	Sigma Receptor	Neurological Disease
AD186 is a potent and selective S1R agonist with K_is of 2.7, 27 nM for S1R and S2R, respectively. AD186 fully reverses the antiallodynic effect of BD-1063 (HY-18101A) .

HY-N0304A

L-DOPA sodium Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304S

L-DOPA-d6 Levodopa-d₆; 3,4-Dihydroxyphenylalanine-d₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-110199

TC-I 2014	TRP Channel	Neurological Disease
TC-I 2014 (compound 5) is a potent and orally active Benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonist, with IC₅₀ values of 0.8 nM, 3.0 nM and 4.4 nM for canine, human and rat channels respectively. TC-I 2014 exhibits antiallodynic properties in pain models .

HY-N0304S1

L-DOPA-13C6 Levodopa-¹³C₆; 3,4-Dihydroxyphenylalanine-¹³C₆	Dopamine Receptor Endogenous Metabolite
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0304S2

L-DOPA-13C 1 Publications Verification	Dopamine Receptor Endogenous Metabolite
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-N0304R

L-DOPA (Standard) Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-P4910

Baceridin	Proteasome Apoptosis	Cancer
Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .

HY-N0092

Inosine 5 Publications Verification	Adenosine Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors .

HY-N0092S3

Inosine-13C10,15N4	Adenosine Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Inosine-13C10,15N4 is ¹³C and ¹⁵N labeled Inosine (HY-N0092). Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors .

Baceridin	Proteasome Apoptosis	Cancer
Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0630

Shanzhiside methyl ester	Iridoids Terpenoids Labiatae Source classification Plants Helenium radiatum (Less.) Bierner	GCGR
Shanzhiside methy lester is isolated from lamiophlomis rotata. Shanzhiside methyl ester is a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and has the ability to induce anti-allodynic tolerance .

HY-N0304

L-DOPA Maximum Cited Publications 13 Publications Verification Levodopa; 3,4-Dihydroxyphenylalanine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0092

Inosine 5 Publications Verification	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Adenosine Receptor Endogenous Metabolite
Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors .

HY-N0304A

L-DOPA sodium Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

L-DOPA (Standard) Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

Cat. No.	Product Name	Chemical Structure

HY-N0304S

L-DOPA-d6
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-N0304S2

L-DOPA-13C 1 Publications Verification
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-N0304S1

L-DOPA-13C6
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0092S3

Inosine-13C10,15N4
Inosine-13C10,15N4 is ¹³C and ¹⁵N labeled Inosine (HY-N0092). Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A₁ (A₁R) and A_2A (A_2AR) receptors .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

antiallodynic

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products